Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Chronic glomerulonephritis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Chronic glomerulonephritis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Cardiomyopathy, Restrictive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Cardiomyopathy, Restrictive in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Familial Myelofibrosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Familial Myelofibrosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Spinocerebellar Ataxias Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Spinocerebellar Ataxias in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Visible Lesion Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Visible Lesion with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Tuberculosis, extrapulmonary Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Tuberculosis, extrapulmonary in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Congenital Structural Myopathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Congenital Structural Myopathy in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Neuroendocrine neoplasm of lung Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Neuroendocrine neoplasm of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Clear Cell Sarcoma of Kidney Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Clear Cell Sarcoma of Kidney in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Brittle Bone Disorder Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Brittle Bone Disorder with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Biliary Tract Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Biliary Tract Neoplasms in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Complement Component 3 Deficiency, Autosomal Recessive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Complement Component 3 in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..